A novel open-label, phase II trial recently published in the evaluated the safety and efficacy of balstilimab co-administered with zalifrelimab as second-line treatment for 155 patients with recurrent and/or metastatic cervical cancer who had relapsed after prior platinum-based therapy. In this exclusive MedPage Today interview, , section head of Obstetrics and Gynecology and the Women's Health Institute at the Cleveland Clinic, reviews the results of the study and offers his takeaways.